Numan, based in London, addresses the widespread health issue of erectile dysfunction (ED) with a direct-to-consumer model. Offering a personalized approach, it stands out compared to traditional doctor visits or over-the-counter medications. By focusing on ED, Numan aims to alleviate personal distress, relationship issues, and potential health complications. Supported by investors like Anthemis and VNV Global, the startup is well-positioned to tap into a niche market with high demand and limited specialized options.